Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-371-8300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.42 million
Profitability
Miscellaneous
Employees40
Next Earnings Date11/18/2019 (Estimated)
OptionableNot Optionable
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
What is Jaguar Health's stock symbol?
Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."
How were Jaguar Health's earnings last quarter?
Jaguar Health Inc (NASDAQ:JAGX) announced its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($9.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by $3.48. The biotechnology company had revenue of $1.71 million for the quarter, compared to the consensus estimate of $3.05 million. Jaguar Health had a negative net margin of 727.27% and a negative return on equity of 698.61%. View Jaguar Health's Earnings History.
When is Jaguar Health's next earnings date?
What price target have analysts set for JAGX?
2 equities research analysts have issued twelve-month price targets for Jaguar Health's stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Jaguar Health's share price to reach $7.50 in the next year. This suggests a possible upside of 934.5% from the stock's current price. View Analyst Price Targets for Jaguar Health.
What is the consensus analysts' recommendation for Jaguar Health?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.
Has Jaguar Health been receiving favorable news coverage?
News coverage about JAGX stock has been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jaguar Health earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Jaguar Health.
Are investors shorting Jaguar Health?
Jaguar Health saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 107,700 shares, a decrease of 26.4% from the August 15th total of 146,400 shares. Based on an average daily volume of 994,700 shares, the short-interest ratio is currently 0.1 days. Currently, 5.9% of the company's shares are short sold. View Jaguar Health's Current Options Chain.
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include Avadel Pharmaceuticals (AVDL), Sesen Bio (SESN), Kala Pharmaceuticals (KALA), Fulcrum Therapeutics (FULC), MEI Pharma (MEIP), OASMIA PHARMACE/ADR (OASM), PhaseBio Pharmaceuticals (PHAS), Mustang Bio (MBIO), Eton Pharmaceuticals (ETON), Paratek Pharmaceuticals (PRTK), Scpharmaceuticals (SCPH), Menlo Therapeutics (MNLO), Helix Biopharma (HBPCF), Adamas Pharmaceuticals (ADMS) and Strongbridge Biopharma (SBBP).
What other stocks do shareholders of Jaguar Health own?
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the folowing people:
- Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 60)
- Ms. Karen S. Wright, CFO & Treasurer (Age 63)
- Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 61)
- Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 56)
- Mr. Jonathan S. Wolin, Chief Compliance Officer & Corp. Counsel
When did Jaguar Health IPO?
(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
How do I buy shares of Jaguar Health?
Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Jaguar Health's stock price today?
One share of JAGX stock can currently be purchased for approximately $0.73.
How big of a company is Jaguar Health?
Jaguar Health has a market capitalization of $33.61 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.
What is Jaguar Health's official website?
How can I contact Jaguar Health?
Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.
MarketBeat Community Rating for Jaguar Health (NASDAQ JAGX)
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
